Frontline treatment with osimertinib led to similar improvements in quality of life, including a clinically meaningful improvement in cough, compared with a standard of care EGFR TKIs for patients with advanced EGFR-mutant non–small cell lung cancer.
Maurice Perol, MD, medical oncologist, Centre Leon Berard, discusses the results of the ALEX trial in ALK-positive non–small cell lung cancer.
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the CheckMate-384 study in non–small cell lung cancer.
Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the quality of life findings from the FLAURA study in non–small cell lung cancer.
In findings consistent with earlier results on efficacy and adverse events reported for the phase III ALEX trial, investigators announced superior patient-reported outcomes for the next-generation tyrosine kinase inhibitor alectinib versus the standard of care TKI inhibitor crizotinib in ALK-positive non–small cell lung cancer.
The frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC.
Anti PD-L1 immunotherapy with atezolizumab (Tecentriq) was strongly superior to docetaxel in locally advanced or metastatic non–small cell lung cancer, according to 3-year survival findings from the phase II POPLAR study.
Currently approved PARP inhibitors have demonstrated similar efficacy in the setting of maintenance therapy for patients with ovarian cancer but differ with respect to the type and frequency of grade 3/4 adverse events, results of a network meta-analysis suggested.
Combination therapy with the PARP inhibitor olaparib and the PD-L1 inhibitor durvalumab induced objective responses in more than 70% of patients with relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.
Brian M. Slomovitz, MD, gynecologic oncologist, Sylvester Comprehensive Cancer Center, University of Miami, discusses GOG 3007, a randomized phase II study of everolimus (Afinitor) and letrozole or hormonal therapy (medroxyprogesterone acetate/tamoxifen) in women with advanced, persistent or recurrent endometrial carcinoma during the 2018 Society of Gynecologic Oncology Annual Meeting.
Jaron Mark, MD, gynecologic oncology fellow, Roswell Park Comprehensive Cancer Center, discusses the implementation of an ultra-restrictive opioid prescription protocol (UROPP) in patients undergoing major gynecologic surgery, which radically decreased dispensed opioids without reducing pain control, during the 2018 Society of Gynecologic Oncology Annual Meeting.
Patients with platinum-resistant/refractory ovarian cancer had durable responses with the combination of the PARP inhibitor niraparib (Zejula) and pembrolizumab (Keytruda).
Almost half of patients with platinum-resistant ovarian cancer had objective responses to combination therapy with pembrolizumab plus the antifolate antibody-drug conjugate mirvetuximab soravtansine.
Lavanya Palavalli Parsons, MD, clinical fellow, The University of Texas Southwestern Medical Center, discusses the role of PARP 7 in overall survival of patients with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.
Patients with HER2-positive uterine serous carcinoma had a greater than 50% improvement in progression-free survival when treated with trastuzumab and chemotherapy versus chemotherapy alone, a small randomized trial showed.
Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.
To access the value of the maintenance therapies and biomarkers to direct treatment for patients with platinum-sensitive recurrent ovarian cancer, investigators used ASCO’s Net Health Benefit and ESMO’s Magnitude of Clinical Benefit Scale.
Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting.
Baseline body weight and platelet counts were early predictors for future AE-related dose modifications for niraparib (Zejula) in women with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Implementation of an "ultra-restrictive" opioid prescription protocol for gynecologic surgery led to an 89% reduction in the number of opioid tablets dispensed at discharge and a high rate of patient satisfaction.
Bradley J. Monk, MD, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses how to decide which PARP inhibitor to use when treating a patient with ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.
The use of immune checkpoint inhibitors in women with recurrent ovarian cancer has a clinical benefit but a higher rate of adverse events than previously reported in other tumor types.
Jarushka Naidoo, MBBCh, discusses some of the most commonly seen immune-related adverse events in patients with lung cancer and how to manage them.
Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the important of addressing financial toxicity during the 5th Annual Miami Lung Cancer Conference.
ROS1, NTRK, MET, and HER2 are all less common molecular targets found in non–small cell lung cancer, but emerging therapeutic strategies are being explored to attack these abnormalities.
Heather Wakelee, MD, professor of medicine, division of oncology, Stanford University, discusses first-line therapy for patients with EGFR-mutant lung cancer.
Upfront testing for BRAF V600E mutations is necessary for patients with non–small cell lung cancer, but if results are positive, physicians are unsure when to administer BRAF/MEK combination therapy—and they must be prepared to manage the associated adverse events.
Abemaciclib (Verzenio) has quickly amassed several clinical indications for patients with metastatic breast cancer, and is the only CDK4/6 inhibitor approved as a single agent.
Patrick I. Borgen, MD, chairman of surgery, director of the Breast Cancer Program, Maimonides Medical Center, and chair of the Miami Breast Cancer Conference, discusses the evolution of breast cancer treatment in recent years. Borgen shared his insight in an interview during the meeting.
Heather Wakelee, MD, discusses the rapidly changing landscape of frontline EGFR tyrosine kinase inhibitors in non–small cell lung cancer.
